Media Thread, page-13527

The HER 2 space isn't the only " over crowded " one.

In one of the recent CHM presentations it was stated that almost 300 companies worldwide are trying to develop their own CD 19 CAR-Ts. So far, just 6 autologous CAR-Ts have been approved, 4 are used. The race for the first approved allogenic CAR-T is on and if we've been told the truth then IMU could be the first over the "Approved-Line". The data so far are outstanding considering the patients being trialed. And that's the strange thing.

If Azer-Cel is really the best or among the best and most advanced CD 19 CAR-T out there why hasn't any of the big guys snapped it up? Novartis just paid about USD1b for a radio therapy comp but, as the 3rd largest sh of Precision, can't or won't find a few USD million for the best CD 19 CAR-T? Again, using CHM's leaving CEO as a source, the "300 CD 19 CAR-T hunters" range from small to the biggest guys, why hasn't any of those made a move at IMU?

Hopper is or at least has been well connected to Novartis, Merck, Roche....- maybe something is brewing in the background or Hopper just fell for the oldest " Buy our gem which is the biggest crap " - trick.

Pfitzer bought a useless "Cough in the phone app" for AUD 150m? but none of the biggest guys is interested in the best cancer fighting treatment since sliced bread? Something doesn't add up.

The OV market is just re-emerging, new technologies made it possible. Again, IMU seems to be in the front and the data so far are fantastic. And yet, the big guys who are part of the race aren't interested in one of the best front runners when they can get it for pocket money?

Either Hopper is negotiating in the background and everyone is really tightlipped or we have been told lies. By the way, we haven't heard from Prof Fong for a while, Hopper fired RAD's Baker, CHM's CEO is leaving......

I just hope that it will end good.

GLTA